Hazard Information | Back Directory | [Uses]
Lanadelumab (SHP643) is a human IgG1 monoclonal antibody against plasma kallikrein (pKal) with an Ki value of 0.12 nM. Lanadelumab inhibits both free and HMWK (high molecular weight kininogen)-bound pKal. Lanadelumab has the potential for the research of hereditary angioedema[1][2]. | [in vivo]
Lanadelumab (20 mg/kg; i.v. or s.c.) shows a long half-life of about 12.5 days and blocks high molecular weight kininogen proteolysis in activated plasma in a dose- and time-dependent manner in cynomolgus monkeys[2].
Lanadelumab (1, 30 mg/kg; s.c.) inhibits carrageenan-induced paw edema in the Male Sprague-Dawley rats [2]. | [References]
[1] Riedl MA, et al. Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks. Allergy. 2020 Nov;75(11):2879-2887. DOI:10.1111/all.14416 [2] Kenniston JA, et al. Inhibition of plasma kallikrein by a highly specific active site blocking antibody. J Biol Chem. 2014 Aug 22;289(34):23596-608. DOI:10.1074/jbc.M114.569061 |
|
Company Name: |
Biolab Reagents
|
Tel: |
18108604356 18108604356 |
Website: |
www.biolabreagent.com/ |
Company Name: |
Cell Sciences
|
Tel: |
9785721070 |
Website: |
www.cellsciences.com |
|